Compare Quest Diagnostics Inc (DGX) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Matson Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Matson Inc trades at $225.53 (market cap $6.81B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× Matson Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Matson Inc for 23 Days on average.
| DGX | MATX | |
|---|---|---|
Market Cap | $25.48B | $6.81B |
Volume | 941,866 | 255,080 |
Sector | Health | Industrials |
52-Week High | $247.45 | $238.60 |
52-Week Low | $173.49 | $88.05 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $31.23B | $7.41B |
Dividend Yield | 1.49% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Matson (MATX) trades at $225.67, up 1.23% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 12.7% and raising full-year guidance. Revenue growth continues with 2026 projections of $3.5B and net profit margins above 13%. Recent institutional buying from Bank of New York Mellon and Deutsche Bank highlights confidence in the shipping company's prospects.
MATX presents a compelling investment case with strong earnings momentum, reasonable valuation (P/E 15.37), and positive analyst sentiment (67% buy ratings). Key risks include freight market cyclicality and competitive pressures. The stock's 27.3% upside potential based on analyst targets and consistent dividend payments ($0.38 declared for H2-26) support a favorable outlook for value-oriented investors seeking transportation sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
